BridgeBio Pharma, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
BBIO Nasdaq 2836 bridgebio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BridgeBio Pharma, Inc.

Here Are Wednesday’s Top Wall Street Analyst Research Calls: Boyd Gaming, Chipotle Mexican Grill, Conagra, Dollar General, MGM Resorts International, Omnicom Group, Yum! Brands, and More - Jun 3rd, 2026 11:08 am
Yum! Brands upgraded, Chipotle downgraded: Wall Street's top analyst calls - Jun 3rd, 2026 7:55 am
Does FDA Priority Review for First LGMD Therapy Change The Bull Case For BridgeBio Pharma (BBIO)? - May 31st, 2026 9:07 pm
Allogene CEO to step down; Agios drug fails key test - May 29th, 2026 4:17 am
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9 - May 27th, 2026 5:30 am
Intel downgraded, Marvell upgraded: Wall Street's top analyst calls - May 26th, 2026 7:34 am
Citi Initiates BridgeBio at Neutral: Why the Cardiomyopathy Story Isn’t a Slam Dunk - May 19th, 2026 10:15 am
StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls - May 19th, 2026 7:34 am
How Encaleret’s NDA and New Acoramidis Milestones Could Reframe BridgeBio Pharma (BBIO) Investors’ Outlook - May 14th, 2026 11:13 pm
Evercore ISI Retains an “Outperform Rating” on BridgeBio Pharma, Inc. (BBIO) - May 13th, 2026 11:53 am
BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches - May 12th, 2026 11:04 pm
BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial - May 12th, 2026 5:39 am
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1 - May 12th, 2026 5:30 am
Analysts Are Updating Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Estimates After Its First-Quarter Results - May 11th, 2026 8:46 am
Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure - May 11th, 2026 7:30 am
BridgeBio Brazil Approval Expands BEYONTTRA Reach While Valuation Signals Upside - May 9th, 2026 12:14 am
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - May 8th, 2026 2:01 pm
BridgeBio (BBIO) Q1 2026 Earnings Transcript - May 8th, 2026 7:03 am
BridgeBio Pharma Q1 Earnings Call Highlights - May 7th, 2026 5:42 pm
BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates - May 7th, 2026 3:25 pm